AmerisourceBergen

KYCO: Know Your Company

Reveal Profile

28 October 2025

1) Overview of the Service Provider

AmerisourceBergen Corporation, now operating as Cencora following its August 2023 rebrand, is a leading global pharmaceutical solutions organization that serves as a critical intermediary in the healthcare supply chain. The company generates over $294 billion in annual revenue and employs approximately 46,000-51,000 team members worldwide, operating through over 1,300 locations across more than 50 countries.

Cencora operates through two primary segments: U.S. Healthcare Solutions, which generated $265.3 billion in fiscal 2024 revenue, and International Healthcare Solutions, contributing $28.6 billion. The company’s comprehensive service portfolio spans pharmaceutical distribution, specialty logistics, patient access services, commercialization support, and clinical consulting through subsidiaries including World Courier, PharmaLex, Alliance Healthcare, and MWI Animal Health.

The company maintains dominant market positioning within the pharmaceutical distribution oligopoly, controlling approximately one-third of the U.S. drug distribution market alongside Cardinal Health and McKesson Corporation. Together, these three companies supply over 90% of the U.S. pharmaceutical distribution market. Cencora’s extensive distribution network includes 50+ U.S. distribution centers, nine Canadian facilities, and four specialty distribution centers, processing over 4 million units daily.

Cencora serves a diverse client base spanning nearly 100% of U.S. hospitals, 34% of U.S. retail pharmacies, over 67,000 community practices, and more than 1,500 pharmaceutical manufacturers. The company’s specialty services focus on high-growth therapeutic areas including GLP-1 diabetes medications, oncology treatments, and cell and gene therapies, which provide higher margins than traditional distribution services.

The company trades on the New York Stock Exchange under ticker symbol COR and is ranked #11 on the Fortune 500 and #24 on the Global Fortune 500. With total assets of $67.1 billion as of fiscal 2024, Cencora maintains its position as one of the world’s largest pharmaceutical services companies, benefiting from strong relationships with both pharmaceutical manufacturers and healthcare providers that create switching barriers and sustainable competitive advantages.

2) History

The origins of AmerisourceBergen Corporation trace back to 1871, when 17-year-old Lucien Napoleon Brunswig began his apprenticeship with a U.S. druggist after emigrating from France. Brunswig progressed from apprentice to business owner, establishing a retail drug store in Atchison, Kansas, before expanding westward to Fort Worth, Texas, where his drugstore achieved $350,000 in annual sales by 1883. In 1882, Brunswig partnered with George R. Finlay in New Orleans, forming Finlay and Brunswig, which became The Brunswig Drug Company in 1907 after Brunswig acquired full control following Finlay’s death.

Parallel to Brunswig’s development, Emil P. Martini opened a pharmaceutical retail outlet in Hackensack, New Jersey in 1928, which he converted into the Bergen Drug Company in 1947. Bergen distinguished itself as an early technology adopter, becoming the first wholesale drug company in the United States to use computerized punch cards for inventory tracking in 1947 and the first to use computers for inventory control and accounting in 1959. Bergen Drug Company’s innovative approach proved successful, enabling it to acquire The Brunswig Drug Company in 1969, creating the Bergen Brunswig Corporation.

The AmeriSource lineage began when Alco Standard Corporation entered pharmaceutical distribution in 1977 by acquiring The Drug House, a major Pennsylvania and Delaware wholesaler. Through aggressive expansion in the early 1980s, Alco Standard’s pharmaceutical distribution network became the third largest in the nation, acquiring companies including Kauffman-Lattimer, Smith-Higgins, and Geer Drug. In 1985, Alco Standard spun off its drug distribution operations as Alco Health Services Corporation, which changed its name to AmeriSource Health Corporation in 1994.

The formation of modern AmerisourceBergen occurred through the August 29, 2001 merger of equals between AmeriSource Health Corporation and Bergen Brunswig Corporation, creating a new industry leader with approximately $36 billion in annualized operating revenue and 103 million shares outstanding. The merger established Valley Forge, Pennsylvania as headquarters, with R. David Yost serving as President and Chief Executive Officer and Robert E. Martini as Chairman. The transaction was structured to achieve over $125 million in annual pre-tax operating savings by the third anniversary through distribution center consolidation, corporate staff optimization, and purchasing efficiencies.

Following the merger, AmerisourceBergen embarked on an extensive acquisition strategy to expand its capabilities and market reach. Key acquisitions included Bellco Health for $162.2 million in October 2007, World Courier Group for $520 million in March 2012, and MWI Veterinary Supply for $2.5 billion in January 2015. The company’s most transformative acquisition was Alliance Healthcare from Walgreens Boots Alliance for $6.275 billion in cash plus 2 million shares in June 2021, significantly expanding its international presence and global manufacturer services.

In August 2023, AmerisourceBergen completed its transformation to Cencora, Inc., reflecting its evolution from a U.S.-focused pharmaceutical distributor to a global healthcare solutions organization. The rebranding unified the company’s 46,000 employees across multiple global business segments under one identity, with the new ticker symbol “COR” beginning trading on the New York Stock Exchange on August 30, 2023. This transformation marked the culmination of over two decades of strategic growth, positioning Cencora as a leading global pharmaceutical solutions provider with operations spanning more than 50 countries and annual revenues exceeding $294 billion by fiscal 2024.

3) Key Executives

Robert P. Mauch became President and Chief Executive Officer of Cencora in October 2024, succeeding Steven H. Collis who transitioned to Executive Chairman. Mauch holds a PharmD from Mercer University and a PhD in pharmaceutical science from the University of South Carolina with a focus in health economics and outcomes research. He began his pharmaceutical care career as founder of Xcenda (formerly Applied Health Outcomes), which provided health economics and strategic consulting to pharmaceutical companies before Cencora acquired it in 2007. Mauch previously served as Executive Vice President and Chief Operating Officer from October 2022 to September 2024, leading all of Cencora’s domestic and international business units.

James F. Cleary serves as Executive Vice President and Chief Financial Officer for Cencora since November 2018. Cleary joined the company in February 2015 when Cencora acquired MWI Veterinary Supply, where he had served as Chief Executive Officer for over a decade. Prior to his current role, he was Group President of Global Commercialization Services and Animal Health, overseeing pharmaceutical commercialization solutions for manufacturers and the company’s international businesses. He graduated from Dartmouth College with a Bachelor of Arts in economics and received his Master of Business Administration from Harvard Business School.

Jennifer Dubas serves as Senior Vice President and Chief Compliance Officer since September 2022. She previously held the position of Vice President and Senior Compliance Officer at Cencora from January 2019 to September 2022. Before joining Cencora, Dubas held senior roles in legal and compliance departments at Endo Pharmaceuticals, serving as head of litigation, lead commercial attorney, and ultimately as Chief Compliance Officer. She graduated from Bryn Mawr College and received her Juris Doctorate from Temple University James E. Beasley School of Law.

Pawan Verma was appointed Executive Vice President and Chief Data and Information Officer in November 2024. Verma joined Cencora from MetLife, where he served as Executive Vice President and Global Chief Information Officer, overseeing an organization of 10,000 people and spearheading the company’s digital transformation. Previously, he served as Chief Information and Customer Experience Officer at Foot Locker, leading a 4,000-member team to transform technology, data, and supply chain ecosystems, work that earned him the Forbes CIO Innovation Award. He holds a Bachelor of Science in mathematics, Master of Computer Application in software engineering, and Master of Business Administration from Kent State University.

Francois Mandeville was appointed Executive Vice President, Strategy and M&A in November 2024. Mandeville brings extensive experience in leading M&A strategies to drive business growth, having most recently served as Chief Development Officer at Johnson Controls. Prior to that, he worked at Danaher Corporation as Senior Vice President, Strategy & Business Development, where he helped propel business growth from $2.2 billion in 2011 to over $15 billion in 2021. Mandeville also had a 25-year tenure at Agilent Technologies, where he led R&D teams, new business incubation, and M&A target identification and integration.

Lazarus Krikorian serves as Senior Vice President and Corporate Controller for Cencora. He was named to his current role in 2012, having previously served as Vice President and Assistant Corporate Controller since joining the company in 2002. Prior to joining Cencora, he held other financial management positions, including Senior Assurance Manager at KPMG LLP, where he spent a decade. He holds a Bachelor of Science in the dual major of Accounting and Finance from Drexel University.

4) Ownership

Cencora operates as a publicly traded company on the New York Stock Exchange under ticker symbol “COR” since its August 2023 rebranding from AmerisourceBergen Corporation. The company maintains a diversified ownership structure primarily dominated by institutional investors, with approximately 193.88 million shares outstanding and a market capitalization of approximately $64.5 billion as of October 2025.

Institutional ownership represents the predominant shareholder base, with major asset management firms holding significant stakes in the company. The Vanguard Group, Inc. stands as the largest institutional shareholder with approximately 8.2% ownership, equivalent to over 16.4 million shares. BlackRock, Inc. follows as the second-largest institutional holder with approximately 6.5% ownership representing over 13.2 million shares. Other significant institutional shareholders include FMR LLC (Fidelity) with 5.9% ownership, State Street Corporation with 4.8%, and Wellington Management Group LLP with 4.3%.

Walgreens Boots Alliance historically maintained the largest individual shareholder position in Cencora, but has systematically reduced its stake through multiple share sales. In August 2023, Walgreens sold $1.85 billion worth of Cencora shares, reducing its ownership to approximately 16%. This divestiture continued a pattern of strategic share sales, including a $694 million transaction in May 2023 and a $1.0 billion offering in November 2022. The relationship between the companies originated from a 2013 strategic partnership that granted Walgreens and Alliance Boots equity warrants exercisable for up to 23% of Cencora’s fully diluted equity, with initial rights to purchase up to 7% in the open market.

The company’s capital structure reflects significant leverage, with a debt-to-equity ratio of approximately 4.83 as of fiscal 2024, substantially higher than the industry average of around 1.0. Total debt comprises $576.3 million in short-term obligations and $3.8 billion in long-term debt, supporting the company’s growth initiatives and acquisition strategy. Cencora maintains investment-grade credit ratings of Baa2 from Moody’s and BBB from S&P, reflecting stable financial standing despite elevated leverage levels.

Insider ownership remains limited, with executive leadership and board members collectively holding approximately 1.9% of outstanding shares. The company has implemented active share repurchase programs, reducing diluted shares outstanding to approximately 200.3 million shares while consistently paying quarterly dividends, with the most recent dividend increased 8% to $0.55 per share in November 2024.

5) Legal Claims and Actions

AmerisourceBergen Corporation and its subsidiaries face significant ongoing litigation primarily related to opioid distribution practices, with additional matters involving employment discrimination, regulatory compliance, and commercial disputes. The most material legal challenges center on the company’s role in the opioid epidemic through its distribution subsidiary AmerisourceBergen Drug Corporation.

The company confronts substantial opioid-related litigation, most notably the ongoing appeals process in West Virginia federal courts. In May 2025, the United States Court of Appeals for the Fourth Circuit certified a question to the Supreme Court of Appeals of West Virginia regarding whether conditions caused by controlled substance distribution can constitute a public nuisance under state common law. This emerged from lawsuits filed by the City of Huntington and Cabell County Commission against AmerisourceBergen Drug Corporation, Cardinal Health, and McKesson Corporation, alleging the companies “created, perpetuated, and maintained” the opioid epidemic by shipping excessive quantities of opioids to pharmacies despite knowing such quantities exceeded legitimate market needs. After a ten-week bench trial, the federal district court ruled in favor of the defendant distributors in July 2022, but plaintiffs appealed, arguing the court misinterpreted the Controlled Substances Act and erroneously found no causation between distributors’ conduct and the opioid epidemic.

Additional opioid litigation includes a June 2021 case where AmerisourceBergen Drug Corporation petitioned the Supreme Court of Appeals of West Virginia challenging Mass Litigation Panel rulings regarding jury trial rights for public nuisance claims and the applicability of West Virginia’s comparative fault statute. The court granted the petition in part, determining that juries must first decide issues common to public nuisance liability and plaintiffs’ legal claims.

In regulatory enforcement actions, AmerisourceBergen Drug Corporation settled significant controlled substances violations with the West Virginia Attorney General in June 2012 for $16.0 million. The settlement dismissed with prejudice allegations that the company failed to provide effective controls against controlled substance diversion, acted negligently by distributing to pharmacies serving substance abusers, and failed to report suspicious orders in accordance with state regulations.

The company achieved a notable legal victory in New York’s constitutional challenge to the Opioid Stewardship Act, obtaining a $57.4 million refund in May 2024. The New York Court of Appeals found the Act’s retroactive application to 2017 violated due process, though upheld its validity for 2018 forward.

AmerisourceBergen’s specialty healthcare subsidiary ASD Specialty Healthcare faces serious Anti-Kickback Statute violations, agreeing to pay $1.67 million in December 2024 to resolve allegations of providing free inventory management software to retina practices conditioned on purchasing agreements. The Department of Justice alleged this violated the Anti-Kickback Statute and caused submission of false claims to Medicare, TRICARE, and the Department of Veterans Affairs.

Employment-related litigation includes multiple civil rights discrimination cases across various subsidiaries. Recent matters include Angela Parker v. AmerisourceBergen Services Corporation filed in February 2024 and dismissed with prejudice in April 2025 following settlement negotiations. Additional employment discrimination cases involve Daryl Osbrink v. AmerisourceBergen Drug Corporation, settled in June 2024, and Dolores Zolotor v. MWI Veterinary Supply, Inc., resolved through stipulated dismissal in July 2024.

Commercial litigation includes ASD Specialty Healthcare’s successful collection action against Community First Healthcare of Illinois, obtaining a $484,167.26 judgment plus 18% annual interest in February 2023 for unpaid COVID-19 treatment drug purchases. The court granted summary judgment on both breach of contract and account stated claims.

Historical matters include a 2002 case where AmerisourceBergen Corporation unsuccessfully sued Dialysist West for breach of sales agreement involving allegedly counterfeit Epogen products, ultimately owing approximately $2.2 million to Dialysist West after losing on appeal. The company also faced derivative litigation in 2014 regarding MWI Veterinary Supply director stock grants alleged to violate fiduciary duties and the company’s stock incentive plan.

6) Recent Media Coverage

AmerisourceBergen, which rebranded as Cencora in August 2023, continues to face significant legal and regulatory scrutiny, primarily related to its historical role in the U.S. opioid crisis. In October 2025, a U.S. appeals court revived a $2.5 billion lawsuit brought by communities in West Virginia, overturning a 2022 trial verdict in the company’s favor. The revived suit alleges the company created a “public nuisance” by failing to report suspicious opioid orders. Separately, the company’s directors agreed in August 2025 to a $111.3 million settlement to resolve a shareholder derivative lawsuit over failed board oversight of opioid distribution. This came after the Delaware Supreme Court revived the case in December 2023, finding that directors faced a substantial likelihood of liability for ignoring “a tidal wave of red flags.”

The U.S. Department of Justice also filed a nationwide lawsuit against the company in late 2022, alleging it failed to report hundreds of thousands of suspicious opioid orders for nearly a decade, thereby “fueling the opioid crisis.” The complaint, which seeks potential penalties in the billions of dollars, accuses the company of intentionally altering its internal monitoring systems to reduce the number of orders flagged as suspicious. In a separate matter, Cencora and other distributors agreed in September 2024 to pay $300 million to settle claims brought by health insurers over costs associated with the opioid epidemic. These actions follow a broader $26 billion national settlement framework reached in 2022 with state and local governments, under which Cencora’s share is approximately $6.1 billion payable over 18 years.

In early 2024, Cencora experienced a significant cybersecurity incident that resulted in the exfiltration of sensitive personal and health information belonging to patients of its pharmaceutical clients. By May 2024, the company began notifying affected individuals and disclosed that partners including Bristol Myers Squibb, Novartis, GSK, and Pfizer were impacted by the breach at its Lash Group patient services unit. The incident led to class-action litigation, which Cencora agreed to settle for $40 million in August 2025.

The company announced a planned leadership succession in March 2024, with CEO Steven H. Collis set to transition to the role of Executive Chair on October 1, 2024. Robert P. Mauch, the current Chief Operating Officer, was named as the incoming President and CEO. This follows years of investor pressure regarding corporate governance, including campaigns to separate the CEO and Board Chair roles and to link executive compensation more directly to the financial impact of legal settlements.

Amid these challenges, the company has pursued strategic growth, completing its acquisition of global consulting firm PharmaLex in January 2023 and announcing a partnership with TPG in April 2023 to acquire specialty practice network OneOncology in a transaction valued at $2.1 billion. Cencora also became the exclusive distribution partner for the nonprofit generic drug company Civica in early 2023. However, the company and its peers face broader industry oversight, including a U.S. Federal Trade Commission inquiry launched in February 2024 to investigate the causes of drug shortages and the market power of large wholesale distributors.

7) Strengths

Scale and Market Position

AmerisourceBergen operates as one of the world’s largest pharmaceutical solutions organizations, generating over $294 billion in annual revenue and maintaining approximately one-third of the U.S. drug distribution market alongside Cardinal Health and McKesson Corporation. The company’s dominant market positioning within the pharmaceutical distribution oligopoly provides significant competitive advantages, with the three major distributors collectively supplying over 90% of the U.S. pharmaceutical distribution market. This scale enables superior purchasing power and operational leverage that smaller competitors cannot match.

Comprehensive Distribution Network

The company maintains an extensive and sophisticated distribution infrastructure comprising over 50 U.S. distribution centers, nine Canadian facilities, and four specialty distribution centers that process over 4 million units daily. This network reaches nearly 100% of U.S. hospitals, 34% of U.S. retail pharmacies, and over 67,000 community practices, providing unparalleled market access and customer coverage. The company’s investment of over $800 million in distribution infrastructure and operations over the past decade has enhanced quality and efficiency throughout the supply chain.

Technology and Innovation Leadership

AmerisourceBergen has established itself as a technology leader through substantial investments in automation, data analytics, and digital transformation initiatives. The company’s sales performance management tools have demonstrated measurable results, with users experiencing 3-4% revenue growth compared to non-adopters. Advanced warehouse management systems and automation technologies, including state-of-the-art robotics and RFID-enabled inventory management, provide operational efficiency advantages that enhance customer service and reduce costs.

Specialty Pharmaceutical Expertise

The company has built strong capabilities in the rapidly growing specialty pharmaceutical sector, which represents $14.6 billion in total revenue and includes 138,000 specialty products shipped daily. AmerisourceBergen’s expertise in handling complex therapies requiring special temperature controls, including cell and gene therapies, positions the company advantageously as the pharmaceutical industry increasingly focuses on specialty and personalized medicine. The company’s acquisition of World Courier in 2012 further strengthened its global specialty logistics capabilities.

Strategic Partnerships and Customer Relationships

AmerisourceBergen has cultivated deep, long-term partnerships with key industry players, including the strategic relationship with Walgreens Boots Alliance that has doubled throughput at the company’s distribution centers. The company’s Good Neighbor Pharmacy network has consistently ranked highest in customer satisfaction with chain drug store pharmacies in J.D. Power studies, earning this recognition eight times in the last ten years. These relationships create switching barriers and provide sustainable competitive advantages through integrated operations and shared purchasing power.

Financial Strength and Capital Resources

The company maintains strong financial fundamentals with investment-grade credit ratings of Baa2 from Moody’s and BBB from S&P, providing access to capital markets for strategic investments and acquisitions. AmerisourceBergen’s consistent cash flow generation enables continued investment in technology, infrastructure, and strategic initiatives while maintaining regular dividend payments and share repurchase programs. This financial flexibility supports the company’s ability to adapt to market changes and pursue growth opportunities.

8) Potential Risk Areas for Further Diligence

Ongoing Opioid-Related Legal and Regulatory Exposure

Cencora faces substantial ongoing legal liability related to its role in the opioid crisis, with multiple unresolved matters presenting significant financial and reputational risks. The U.S. Department of Justice filed a nationwide lawsuit in December 2022 alleging hundreds of thousands of Controlled Substances Act violations, seeking potential penalties in the billions of dollars. This case remains active, with the federal court denying Cencora’s motion to compel production of internal DEA documents in January 2025. Additionally, a U.S. appeals court revived a $2.5 billion West Virginia lawsuit in October 2025, overturning a 2022 trial verdict in the company’s favor. The company’s $6.1 billion share of the national opioid settlement represents ongoing cash outflows over 18 years, while unresolved litigation continues to expose the company to additional financial penalties and operational restrictions.

Cybersecurity Vulnerabilities and Data Protection Weaknesses

The February 2024 cyberattack on Cencora’s systems revealed significant cybersecurity vulnerabilities that resulted in the theft of sensitive personal and health information belonging to patients of pharmaceutical clients. The breach affected at least 27 pharmaceutical companies including Bristol Myers Squibb, Novartis, GSK, and Pfizer, ultimately impacting over 1.43 million individuals. The company agreed to pay $40 million to settle class-action litigation related to this breach in August 2025. The incident exposed weaknesses in data protection protocols across Cencora’s patient services units, and the company’s delay in notifying affected individuals for nearly three months after discovering the breach raises concerns about incident response procedures. Given the sensitive nature of patient health information handled across Cencora’s network, future cybersecurity incidents could result in substantial regulatory penalties, litigation costs, and damage to pharmaceutical manufacturer relationships.

Concentrated Market Structure and Regulatory Scrutiny

Cencora operates within a highly concentrated pharmaceutical distribution oligopoly alongside Cardinal Health and McKesson Corporation, collectively controlling over 90% of the U.S. market. This concentration has attracted increased regulatory scrutiny, including a U.S. Federal Trade Commission inquiry launched in February 2024 to investigate potential market manipulation and the causes of drug shortages. The oligopolistic structure creates regulatory risk as government agencies may implement new restrictions on distributor practices or pursue antitrust actions that could limit the company’s market share or operational flexibility. Additionally, the concentrated market position makes Cencora vulnerable to reputational damage from industry-wide issues, as demonstrated by the collective opioid litigation affecting all major distributors.

High Financial Leverage and Debt Service Obligations

Cencora maintains a debt-to-equity ratio of approximately 4.83, substantially higher than the industry average of around 1.0, indicating significant financial leverage. The company’s total debt comprises $576.3 million in short-term obligations and $3.8 billion in long-term debt, creating substantial debt service requirements. While the company maintains investment-grade credit ratings of Baa2 from Moody’s and BBB from S&P, the elevated leverage levels could constrain financial flexibility during market downturns or unexpected settlement payments. Rising interest rates pose additional risk to refinancing costs, and the company’s ability to fund growth initiatives or weather financial shocks may be limited by its current capital structure.

Complex Global Operations and Integration Challenges

The company’s extensive international footprint spanning more than 50 countries creates operational complexity and integration risks, particularly following major acquisitions like Alliance Healthcare for $6.275 billion in 2021. Managing diverse regulatory environments, currency exposures, and varying business practices across multiple jurisdictions increases operational risk and compliance burden. The company reported a $418 million goodwill impairment charge related to PharmaLex in fiscal 2024, demonstrating the financial risks associated with international acquisitions and integration challenges. Foreign exchange rate fluctuations and geopolitical tensions could impact the profitability of international operations, while differing regulatory requirements across jurisdictions may create compliance gaps or operational inefficiencies.

Leadership Transition and Succession Planning Risks

The company announced a leadership succession plan in March 2024, with CEO Steven H. Collis transitioning to Executive Chairman and Robert P. Mauch becoming President and CEO in October 2024. While this represents planned succession, leadership transitions during ongoing legal challenges and regulatory scrutiny create execution risk. The company faces pressure from shareholder activists who have campaigned for governance reforms, including separating the CEO and Board Chair roles and linking executive compensation more directly to legal settlement impacts. Management continuity during the transition period is critical for maintaining operational performance and managing ongoing litigation effectively.

Regulatory Compliance and Controlled Substance Monitoring

Despite investments in compliance programs, Cencora continues to face challenges in controlled substance monitoring and regulatory adherence. The Department of Justice complaint alleges that the company intentionally altered its monitoring systems to reduce the number of orders flagged as suspicious, highlighting potential systemic compliance deficiencies. The company operates under a 2007 DEA settlement requiring implementation of compliance programs designed to detect and prevent controlled substance diversion, and failure to maintain these standards could result in license suspensions or additional regulatory penalties. Congressional investigations have found that Cencora reported significantly fewer suspicious orders than competitors despite handling similar volumes, suggesting ongoing compliance risks in controlled substance distribution.

Save as PDF